GSK in quest to be best not first in race for COVID19 vaccine Reuters Discover Thomson ReutersFinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax AccountingBlog Answers OnInnovation Thomson ReutersDirectory of sitesLoginContactSupportBusinessMarketsWorldPoliticsTVMoreUnited States Health NewsJune 19 2020 637 PM 3 days agoGSK in quest to be best not first in race for COVID19 vaccineLudwig Burger4 Min ReadFRANKFURT Reuters There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus the worlds largest vaccine maker GlaxoSmithKline GSKLFILE PHOTO A GlaxoSmithKline GSK sign at the GSK research centre in Stevenage Britain November 26 2019REUTERSPeter NichollsFile PhotoAnd that is absolutely fine according to the British groups chief medical officer for vaccines Thomas Breuer who says the company prefers the slow and steady approach of focusing on an established technology that has the best chance of reaching the widest possible demographicModerna MRNAO the University of Oxford in collaboration with AstraZeneca AZNL and an alliance of BioNTech BNTXO and Pfizer PFEN grabbed headlines by moving to human trials from as early as MarchGSK which is in seven collaborations with institutions or firms globally only entered the clinical trial stage with one project on FridayWe want to be best in class and if others are a little faster I will congratulate them because they can take care of maybe the healthcare workers in selected countries but the world needs billions of doses and we will contribute to this effort Breuer told ReutersGSK aims to contribute a socalled adjuvant an efficacy booster that is combined with more traditional vaccines while the most advanced rival projects use novel genetic technologies and have been accelerated through preclinical testing in labs and on animalsBreuer said vaccines developed later and adjuvant technology may have longer or better efficacy especially in the elderlyAs an example he pointed to GSKs bestseller Shingrix a shingles vaccine with an adjuvant for older people that has swiftly replaced an established rival productThe company laid out plans in May to produce 1 billion doses of the efficacy boosters for COVID19 shots next year compared to the 700 million or so vaccine doses against a range of diseases it usually produces in a yearBreuer said developing a wide range of partnerships was GSKs answer to minimising the risk of failure and allowed it to focus resources on its most promising technology against COVID19 even though it has previously worked on genetic vaccinesThe best thing GSK can offer is making the adjuvant available to more than one companyWe wanted to expose our technology to have several shots on goal he saidGroup CEO Emma Walmsley said in April that an immunisation that works for and is available for most people was unlikely to emerge before the second half of next yearOperation Warp Speed a US push to develop an immunisation shot by contrast wants to have a vaccine available by January 2021GSK is one of more than 100 global players working on vaccines against COVID19 which has killed about 350000 peopleIt has contributed its adjuvant to alliances involving Chinese biotech firms Clover Biopharmaceuticals Xiamen Innovax and Chongqing Zhifei 300122SZ as well as the University of Queensland in Australia and Sanofi SASYPATwo more collaborations are underway but have not been disclosed yet Breuer addedReporting by Ludwig Burger Editing by Kirsten DonovanOur StandardsThe Thomson Reuters Trust Principles0 0narrowbrowserandphonemediumbrowserandportraittabletlandscapetabletmediumwidebrowserwidebrowserandlargermediumbrowserandlandscapetabletmediumwidebrowserandlargerabovephoneportraittabletandaboveaboveportraittabletlandscapetabletandabovelandscapetabletandmediumwidebrowserportraittabletandbelowlandscapetabletandbelowAppsNewslettersAdvertise with UsAdvertising GuidelinesCookiesTerms of UsePrivacyAll quotes delayed a minimum of 15 minutesSee here for a complete list of exchanges and delays 2020 ReutersAll Rights Reserved